Allstocks.com's Bulletin Board Post New Topic  New Poll  Post A Reply
my profile login | register | search | faq | forum home

  next oldest topic   next newest topic
» Allstocks.com's Bulletin Board » Hot Stocks Free for All ! » EVSC

 - UBBFriend: Email this page to someone!    
Author Topic: EVSC
striper
Member


Member Rated:
4
Icon 1 posted      Profile for striper     Send New Private Message       Edit/Delete Post   Reply With Quote 
EVSC Endovasc Submits Protocol for Phase III Clinical Trial of Liprostin
Business Wire - March 6, 2006 9:00 AM (EDT)

MONTGOMERY, Texas, Mar 06, 2006 (BUSINESS WIRE) -- Endovasc, Inc. - (OTCBB: EVSC) a Business Development Company focused on acquiring and investing in innovative drug development in the areas of cardiovascular and metabolic medicine, announced today that the Company has submitted to the U.S. Food and Drug Administration (FDA) its protocol for a Phase IIIa clinical trial of Liprostin(TM) for the treatment of intermittent claudication, a symptom of peripheral arterial disease.

As outlined in the protocol, the Phase IIIa trial is a randomized, Placebo-controlled, double-blinded, pharmacokinetic study of two dose levels of Liprostin(TM) or Placebo administered once-weekly for six weeks. Patients will be followed during the six weeks of infusions and in addition to these sessions, will also be assessed at eight weeks, ten weeks, and four and six months after their first treatment. At the four month follow-up visit, patients, including those assigned to Placebo, may be eligible for open-label treatment with Liprostin. The trial will enroll approximately 60 patients located at six to ten sites in the US.

The primary endpoint of this trial will be the measured change in maximum walking distance from baseline. The trial also consists of several secondary endpoints which include pain free walking distance, limb ischemia scores and the Peripheral Arterial Disease Walking Impairment Questionnaire (PADWIQ).

Diane Dottavio, President and CEO of Endovasc, commented, "Over 4 Million Americans suffer from intermittent claudication for which there is currently no effective drug treatment available. The lack of effective treatment options causes many patients with leg pain resulting from this condition to go untreated."

Intermittent claudication occurs when the arteries that supply blood to the legs become clogged with fatty deposits. This painful condition includes aches or cramps in the calf, buttock, or thigh muscles that occur when patients walk or exercise and stop when they rest.

"The submission of this Phase IIIa protocol represents an important milestone for us and is a result of extensive work and diligence conducted by everyone at Endovasc, including tremendous support from our CRO, Synergos. Armed with compelling results from our previous Phase II study, we are eager to begin enrolling clinical sites," continued Dr. Dottavio.

About Endovasc

Endovasc, Inc., established in 1996, is a Business Development Company focused on acquiring and investing in innovative drug development in the areas of cardiovascular and metabolic medicine. Endovasc's subsidiaries include: Liprostin Inc., which holds the intellectual property for a liposomal based treatment to increase circulation and reduce leg pain in patients suffering from vascular disease; Nutraceutical Development Corporation which has an agreement in place with an innovative product development company to commercialize its muscle mass enhancing product; and Prostent, a stent coating technology.

For more information about Endovasc, please visit www.endovasc.com.

Safe Harbor Statement

o the extent that statements in this press release are not strictly historical, including statements as to business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of Endovasc's product development, events conditioned on stockholder or other approval, or otherwise as to future events, all such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Among the factors which could affect Endovasc's actual results and could cause results to differ from those contained in these forward-looking statements are the risk that financial conditions may change, risks relating to the progress of research and development, the risk that Endovasc will not be able to raise additional capital or enter into additional collaboration agreements. Those associated risks and others are further described in Endovasc's filings with the Securities and Exchange Commission including the most recent reports on Forms 10-KSB, 10-QSB and 8-K, and any amendments thereto.

SOURCE: Endovasc, Inc.

ZA Consulting Inc.
David Zazoff, 212-505-5976

Copyright Business Wire 2006

Posts: 352 | Registered: Jan 2005  |  IP: Logged | Report this post to a Moderator
striper
Member


Member Rated:
4
Icon 1 posted      Profile for striper     Send New Private Message       Edit/Delete Post   Reply With Quote 
BARCHARTS 100% BUY
EVSC - ENDOVASC INC (OTCBB)
Date Open High Low Last Change Volume % Change
03/06/06 0.0575 0.0700 0.0550 0.0670 +0.0140 4190149 +26.42%


Composite Indicator -- Signal -- -- Strength -- -- Direction --
Trend Spotter (TM) Buy Maximum Strongest

Short Term Indicators
7 Day Average Directional Indicator Buy Strong Strongest
10 - 8 Day Moving Average Hilo Channel Buy Strong Strongest
20 Day Moving Average vs Price Buy Maximum Strongest
20 - 50 Day MACD Oscillator Buy Maximum Strongest
20 Day Bollinger Bands Buy Minimum Strongest

Short Term Indicators Average: 100% - Buy

Medium Term Indicators
40 Day Commodity Channel Index Buy Weak Strengthening
50 Day Moving Average vs Price Buy Maximum Strongest
20 - 100 Day MACD Oscillator Buy Maximum Strongest
50 Day Parabolic Time/Price Buy Average Strongest

Medium Term Indicators Average: 100% - Buy

Long Term Indicators
60 Day Commodity Channel Index Buy Weak Strengthening
100 Day Moving Average vs Price Buy Maximum Strongest
50 - 100 Day MACD Oscillator Buy Weak Strongest

Long Term Indicators Average: 100% - Buy

Overall Average: 100% - Buy

Posts: 352 | Registered: Jan 2005  |  IP: Logged | Report this post to a Moderator
   

Quick Reply
Message:

HTML is not enabled.
UBB Code™ is enabled.

Instant Graemlins
   


Post New Topic  New Poll  Post A Reply Close Topic   Feature Topic   Move Topic   Delete Topic next oldest topic   next newest topic
 - Printer-friendly view of this topic
Hop To:


Contact Us | Allstocks.com Message Board Home

© 1997 - 2021 Allstocks.com. All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2

Share